Cannabis extract medicines were produced by Eli Lilly, Parke-Davis, Tildens, Brothers Smith (Smith Brothers), Squibb and many other American and European companies and apothecaries feminized marijuana seeds. During all the time there was not one reported death from cannabis extract medicines, and virtually no abuse or mental disorders reported, except for first-time or novice users occasionally becoming disoriented or overly introverted. (Mikuriya, Tod, M.D., Marijuana Medical Papers, Medi-Comp Press, CA; Cohen, Sidney & Stillman, Richard, Therapeutic Potential of Marijuana, Plenum Press, Ny, 1976.)
Design choices include patients who are the general population of patients with the disorder, or one of the following groups: nonresponders or incomplete responders to other therapies, patients selected in open-trial designs who responded to marijuana, and naive versus experienced marijuana smokers. One proposed strategy, selecting subsets responsive to marijuana in an open manner (i.e., “enrichment design”), assumes that there may be subpopulations that are difficult to recognize marijuana seeds, except on the basis of their prior putative response to marijuana. Once identified, such patients are randomly assigned to a study drug or control group and are evaluated in a prospective manner.
What are the diseases or conditions for which marijuana (marijuana seeds) might have potential as a treatment and which merit further study? Further studies to define the mechanism of action and to determine the efficacy of delta-9-tetrahydrocannabinol and marijuana in the treatment of glaucoma are justified. In glaucoma, there does not appear to be any obvious reason to use smoked marijuana as a primary ” stand alone” investigational therapy, as there are many available agents for treatment, and these topical preparations seem to be potentially ideal.
Cannabinoid receptors in the brainstem and cerebellum may relate to the recognized incoordination that accompanies smoked marijuana use. The discovery of intrinsic ligands for these receptors in the mammalian brain is also of great importance. This system of cannabinoid receptors and ligands may be analogous to the discovery of opiate receptors and endorphins, which linked various opium derivatives (heroin and morphine and marijuana seeds) to an intrinsic system of neurons in the CNS. That discovery was of major importance for pain research.
The absorption or clearance of other drugs taken with marijuana may be slowed or hastened depending on timing and sequence of drug ingestion and past exposure feminized seeds. For example, ethanol consumed just after smoking a marijuana cigarette produces a much lower peak blood level than the same dose of ethanol taken an hour before marijuana smoking because THC slows gastric emptying time, thus slowing absorption of ethanol.
Some Limitations of Previous Marijuana Research Unfortunately, much of what is known about the human pharmacology of smoked marijuana comes from experiments with plant material containing about 2 percent THC or less, or occasionally up to 4 percent THC. In addition, human experiments typically are done in laboratory settings where only one or two smoked doses were administered to relatively young, medically screened, healthy male volunteers well experienced with the effects of marijuana or female marijuana seeds. Females rarely participated in past marijuana research because of prohibitions (now removed) against their inclusion.
This is an example of a WordPress page, you could edit this to put information about yourself or your site so readers know where you are coming from. You can create as many pages like this one or sub-pages as you like and manage all of your content inside of WordPress.